AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04051684
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
Trial: NCT03340753
Drug: KBP-5074 Capsule
RxNorm normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBP-5074 (0.5 mg or 1.0 mg) capsule formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
Trial: NCT03340753
Drug: KBP-5074 Tablet
RxNorm normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBP-5074 (0.5 mg or 1.0 mg) tablet formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
Trial: NCT00005918
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005918
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00005918
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01530594
Drug: Bortezomib/Lenalidomide/ Low dose Dex
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
Trial: NCT01530594
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide/Low dose Dex (LLD
Trial: NCT03525730
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.
Trial: NCT03525730
Drug: Pyrimethamine
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.
Trial: NCT00004748
Drug: colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004748
Drug: ursodiol
RxNorm normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01772264
Drug: PF-05089771
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: titration from 150mg BID to 450mg BID
Trial: NCT03575871
Drug: PF-04965842 100 mg
RxNorm normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
Trial: NCT03575871
Drug: PF-04965842 200 mg
RxNorm normalized name: acetylcysteine
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
Trial: NCT02818387
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
Trial: NCT02818387
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
Trial: NCT01004042
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
Trial: NCT00607152
Drug: Rasburicase
RxNorm normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.20mg/kg per day IV
Trial: NCT00607152
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg tablets
Trial: NCT03072199
Drug: RiTUXimab Injection
RxNorm normalized name: rituximab Injection
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of Rituximab given intravenously within 48hours of myocardial infarction
Trial: NCT00110006
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone once daily on days 1-5. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
Trial: NCT00110006
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine IV over 5 minutes on day 1. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
Trial: NCT00302549
Drug: FK506
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FK506,0.1mg/kg/d
Trial: NCT01478737
Drug: Intravitreal dexamethasone implant
RxNorm normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravitreal Ozurdex after vitrectomy
Trial: NCT01144728
Drug: GLIMEPIRIDE + METFORMIN
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
Trial: NCT03132194
Drug: Aczone
RxNorm normalized name: Aczone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical gel
Trial: NCT03936049
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide dispensing claim is used as the exposure group
Trial: NCT03936049
Drug: DPP-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitor dispensing claim is used as the reference group
Trial: NCT01095679
Drug: Baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
Trial: NCT00700817
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.2 mg once daily, subcutaneous (under the skin) injection
Trial: NCT00700817
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, 100 mg daily
Trial: NCT00700817
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, minimum 1500 mg daily
Trial: NCT00700817
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.8 mg once daily, subcutaneous (under the skin) injection
Trial: NCT03349827
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin: 130mg/m2, day 1. S1: 60mg, twice daily, day 1 to day 14. S1:60mg twice daily for two weeks, and then suspend for one week
Trial: NCT03349827
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg, once daily, day 1 to day 21.
Trial: NCT01123317
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
Trial: NCT01882920
Drug: Conventional Intravenous Fluid therapy
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
Trial: NCT01700478
Drug: Misoprostol + vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
Trial: NCT01700478
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin was used in all patients during surgery.
Trial: NCT03166553
Drug: Elemene
RxNorm normalized name: (-)-B-elemene
DrugBank: (-)-beta-Elemene (DB18097)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00072072
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01338987
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients \<18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients \> 18 years and as a 3 month injection (adult preparation) for patients \< 18 years
Trial: NCT01338987
Drug: 18F FLT
RxNorm normalized name: Fludeoxyglucose (18F)
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
Trial: NCT01338987
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.
Trial: NCT01338987
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Second choice is Busulfan (with goal steady state of 800-1000) with fludarabine or cyclophosphamide at myeloablative dosing or non-myeloablative dosing.
Trial: NCT01338987
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given with Busulfan as alternative to cyclophosphamide in second transplant setting only
Trial: NCT04322578
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib 250mg po bid. Savolitinib 300mg po, qd.
Trial: NCT04322578
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed, 500mg/m2, ivgtt erery 21day.
Trial: NCT00488813
Drug: Third generation cephalosporins
RxNorm normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01369602
Drug: PF-04991532
RxNorm normalized name: PF-04991532
DrugBank: PF-04991532 (DB11765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose 300-mg
Trial: NCT04133649
Drug: AAV-hTERT
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
Trial: NCT00017459
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00017459
Drug: tirapazamine
RxNorm normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00017459
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04478461
Drug: PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W
Trial: NCT00411398
Drug: Namenda/Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg tablets, 1-4 tabs by mouth per day
Trial: NCT01232491
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
Trial: NCT00649727
Drug: Oxybutynin Chloride ER Tablets 10 mg
RxNorm normalized name: oxybutynin chloride Extended Release Oral Tablet
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2x10mg, single dose fed
Trial: NCT00135382
Drug: Videx EC
RxNorm normalized name: Videx EC
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00135382
Drug: Epivir
RxNorm normalized name: Epivir
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00135382
Drug: Sustiva
RxNorm normalized name: Sustiva
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02971982
Drug: rituximab /Dexamethasone/cyclophosphamide
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
Trial: NCT00671073
Drug: Oglemilast
RxNorm normalized name: Oglemilast
DrugBank: Oglemilast (DB12375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oglemilast low dose, oral administration, once daily for 12 weeks
Trial: NCT00671073
Drug: Oglemilast
RxNorm normalized name: Oglemilast
DrugBank: Oglemilast (DB12375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oglemilast middle dose, oral administration, once daily for 12 weeks
Trial: NCT00671073
Drug: Oglemilast
RxNorm normalized name: Oglemilast
DrugBank: Oglemilast (DB12375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oglemilast high dose, oral administration, once daily for 12 weeks
Trial: NCT01487382
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
Trial: NCT01481740
Drug: Phenylephrine bolus
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml of 100mcg/ml phenylephrine and placebo infusion
Trial: NCT01481740
Drug: phenylephrine infusion
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60ml infusion of 100mcg/ml phenylephrine and placebo bolus
Trial: NCT03884101
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
Trial: NCT03884101
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
Trial: NCT03884101
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
Trial: NCT03401073
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
Trial: NCT03401073
Drug: 0.9% Sodium Chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
Trial: NCT00110344
Drug: Nexavar (Sorafenib, BAY43-9006)
RxNorm normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
Trial: NCT00553592
Drug: Bicifadine
RxNorm normalized name: Bicifadine
DrugBank: Bicifadine (DB04889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg/day
Trial: NCT00553592
Drug: Bicifadine
RxNorm normalized name: Bicifadine
DrugBank: Bicifadine (DB04889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet
Trial: NCT00553592
Drug: Bicifadine
RxNorm normalized name: Bicifadine
DrugBank: Bicifadine (DB04889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg
Trial: NCT00706355
Drug: PF-04217903
RxNorm normalized name: PF-04217903
DrugBank: PF-04217903 (DB12848)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
Trial: NCT00455442
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00937651
Drug: Fimasartan (BR-A-657•K) 20 mg
RxNorm normalized name: Respa-BR
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
Trial: NCT00937651
Drug: Fimasartan (BR-A-657•K) 60 mg
RxNorm normalized name: pyridostigmine
DrugBank: Fimasartan (DB09279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
Trial: NCT00937651
Drug: Fimasartan (BR-A-657•K) 180 mg
RxNorm normalized name: pyridostigmine
DrugBank: Fimasartan (DB09279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
Trial: NCT01838928
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03475628
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
Trial: NCT01135628
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide tablets 400 mg, bid, orally for 6 months
Trial: NCT01056094
Drug: Lutein
RxNorm normalized name: Lutein
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
Trial: NCT01229644
Drug: Crenolanib (CP-868,596)
RxNorm normalized name: CP
DrugBank: Crenolanib (DB11832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly potent inhibitor of both PDGFR receptors alpha and beta
Trial: NCT03978091
Drug: AZACTAM
RxNorm normalized name: Azactam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum
Trial: NCT03978091
Drug: Ceftazidime-Avibactam
RxNorm normalized name: avibactam
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An antibacterial combination product containing ceftazidime and avibactam
Trial: NCT00705692
Drug: Levamisole
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00136578
Drug: SB-715992
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
Trial: NCT00136578
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.